A Phase IIIb, Multicentre, Interventional, Randomised, Placebo-Controlled Clinical Trial Investigating the Efficacy and Safety of Guselkumab for the Treatment of Nonpustular Palmoplantar Psoriasis (G-PLUS)

<div>G-PLUS participant disposition. <sup>†</sup>Participants randomised to placebo at the baseline received placebo at weeks 0–16 and then crossed over to guselkumab from week 16 to trial end. All discontinuations occurred after the week 16 visit.</div>

Dermatologic Therapy

fig2

Figure 2

Figure 2: A Phase IIIb, Multicentre, Interventional, Randomised, Placebo-Controlled Clinical Trial Investigating the Efficacy and Safety of Guselkumab for the Treatment of Nonpustular Palmoplantar Psoriasis (G-PLUS) 

Figure 2 | A Phase IIIb, Multicentre, Interventional, Randomised, Placebo-Controlled Clinical Trial Investigating the Efficacy and Safety of Guselkumab for the Treatment of Nonpustular Palmoplantar Psoriasis (G-PLUS) 